EUVIMEDEUVIMED entdecken
Crossref

Design and manufacturing of novel smart pegylated nano-liposome co-encapsulating two herbal compounds: Silibinin and Glycyrrhizic acid with HAb18 monoclonal antibody for targeted co-delivery to liver cancer cells

Mohammad Mahdi Ochi, Ghasem Amoabediny, Seyed Mahdi Rezayat, Azim Akbarzadeh, Bahman Ebrahimi

Nanomedicine Journal · 2026-01 · 13 (1) · 99-114

DOI: 10.22038/nmj.2025.87664.2222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nanomedicine Journal, 2026-01. Verfasst von Mohammad Mahdi Ochi und 4 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective(s): Herbal nano-liposomes, also referred to as nano-Phytosomes, are formed through hydrogen bonding interactions between the phospholipids of lipid membranes and phytomolecules. This structure enhances the delivery efficiency of therapeutic agents. This study focuses on the use of PEGylated nano-liposomes co-loaded with two anti-cancer compounds derived from herbs, silibinin and glycyrrhizic acid, to target liver cancer cells.Materials and Methods: The co-encapsulated nanoscale liposomes were synthesized using the thin-layer film hydration method with HEPES buffer, followed by sonication. The vesicles encapsulating silibinin and glycyrrhizic acid consisted of DPPC, cholesterol, and DSPE-mPEG2000 in a molar percentage ratio of approximately 61.5:35:3.5. A fluorescent label (DIL) was incorporated into the lipid bilayer at a concentration of 0.1 mol%. The multilamellar vesicles were then sonicated and filtered to produce the nano-liposomes. To enhance targeting, these co-encapsulated the nano-liposomes were conjugated with the monoclonal antibody HAb18. The resulting PEGylated nano-liposome formulation demonstrated a narrow size distribution, with an average particle diameter of approximately 45 nm. The zeta potential of the co-encapsulated nano-Phytosome was measured at -23.25mV. The encapsulation efficiencies of silibinin and glycyrrhizic acid were approximately 24.37% and 68.78%, respectively.

Results

The study revealed that the mean diameter of the nano-Phytosome increased upon targeting. Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy (SEM) images confirmed that the average diameters of the targeted co-encapsulated nano-liposomes were approximately 84 nm and 81 nm, respectively, while the monoclonal antibody HAb18 exhibited an average diameter of around 16.1 nm and 15 nm.

Conclusion

This targeted nano-system offers efficient delivery of herbal drugs to liver cancer cells.

Schlagwörter

targetingnano-liposomesilibininglycyrrhizic acidliver cancer

Zitieren

APA

Ochi, M. M., Amoabediny, G., Rezayat, S. M., Akbarzadeh, A., & Ebrahimi, B. (2026). Design and manufacturing of novel smart pegylated nano-liposome co-encapsulating two herbal compounds: Silibinin and Glycyrrhizic acid with HAb18 monoclonal antibody for targeted co-delivery to liver cancer cells. Nanomedicine Journal, 13(1), 99-114. https://doi.org/10.22038/nmj.2025.87664.2222

Vancouver

Ochi MM, Amoabediny G, Rezayat SM, Akbarzadeh A, Ebrahimi B. Design and manufacturing of novel smart pegylated nano-liposome co-encapsulating two herbal compounds: Silibinin and Glycyrrhizic acid with HAb18 monoclonal antibody for targeted co-delivery to liver cancer cells. Nanomedicine Journal. 2026;13(1):99-114. doi:10.22038/nmj.2025.87664.2222

BibTeX
@article{Ochi2026,
  author = {Ochi, Mohammad Mahdi and Amoabediny, Ghasem and Rezayat, Seyed Mahdi and Akbarzadeh, Azim and Ebrahimi, Bahman},
  title = {Design and manufacturing of novel smart pegylated nano-liposome co-encapsulating two herbal compounds: Silibinin and Glycyrrhizic acid with HAb18 monoclonal antibody for targeted co-delivery to liver cancer cells},
  journal = {Nanomedicine Journal},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {99--114},
  doi = {10.22038/nmj.2025.87664.2222}
}
Kostenlos starten →